Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Cambridge Nutritional Sciences EV-to-EBIT?
Cambridge Nutritional SciencesFRA:RVKA EV-to-EBIT is 0.65 as of Aug. 07, 2026. The stock has 3 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks better than 97.44% on this metric.
The historical rank and industry rank for Cambridge Nutritional Sciences's EV-to-EBIT or its related term are showing as below:
FRA:RVKA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -332.32 Med: -4.76 Max: 40.96
Current: 0.66
During the past 13 years, the highest EV-to-EBIT of Cambridge Nutritional Sciences was 40.96. The lowest was -332.32. And the median was -4.76.
FRA:RVKA's EV-to-EBIT is ranked better than 97.44% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 19.13
vs FRA:RVKA: 0.66
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cambridge Nutritional Sciences's Enterprise Value for the quarter that ended in Sep. 2025 was €1.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambridge Nutritional Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was €1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambridge Nutritional Sciences EV-to-EBIT Related Terms
Cambridge Nutritional Sciences EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RVKA vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Nutritional Sciences EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cambridge Nutritional Sciences's EV-to-EBIT falls into.
Cambridge Nutritional Sciences's current Enterprise Value is €1.08 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambridge Nutritional Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 was €1.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cambridge Nutritional Sciences (FRA:RVKA) has a EV-to-EBIT of 0.65 as of Aug. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cambridge Nutritional Sciences and its competitors. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #12 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 2.6%.
Is Cambridge Nutritional Sciences' EV-to-EBIT too high?
Cambridge Nutritional Sciences' current EV-to-EBIT is 0.65. The Medical Devices & Instruments industry median EV-to-EBIT is 19.13. Cambridge Nutritional Sciences' value of 0.65 is 96.6% below this industry median. Based on the distribution chart, Cambridge Nutritional Sciences ranks #12 out of 469 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Cambridge Nutritional Sciences' EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #12 out of 469 companies for EV-to-EBIT. This places Cambridge Nutritional Sciences in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.13. Cambridge Nutritional Sciences' value of 0.65 is 96.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.13, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cambridge Nutritional Sciences's current EV-to-EBIT of 0.65 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current EV-to-EBIT is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 27.5% below its estimated fair value. The current EV-to-EBIT is 0.65 and 96.6% below the Medical Devices & Instruments industry median of 19.13. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current EV-to-EBIT is 0.65 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RVKA has been successfully added to your 
